Alphamab Oncology (HKG:9966)

Market Cap	7.46B +28.1%
Revenue (ttm)	630.11M -11.5%
Net Income	-126.79M
EPS	-0.13
Shares Out	968.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,294,300
Average Volume	1,226,885
Open	7.59
Previous Close	7.74
Day's Range	7.43 - 7.93
52-Week Range	5.30 - 15.75
Beta	0.40
RSI	37.62
Earnings Date	Mar 25, 2026

About Alphamab Oncology

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 484
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9966

Financial Performance

Financial numbers in CNY